The main reason for the improvements in facing leukaemia is "the development of new treatments, combined with good levels of recruitment to UK clinical trials", according to the research's lead author.
Dr Anjali Shah, from the London School of Hygiene & Tropical Medicine and the University of Oxford, added:
These key issues have been effective in curing more people of acute myeloid leukaemia (AML).
But levels of cure of this disease in England remain lower than those observed in other European countries, such as Sweden.
The reasons for these differences are unknown.